This initial dose-escalation study demonstrated a favorable safety ... “BDC-3042 deserves rapid development, especially given its enormous commercial potential. We are launching a process ...

This initial dose-escalation ... No drug-related serious adverse events (SAEs) were reported One NSCLC patient from the 10 mg/kg cohort had an unconfirmed partial response and remains on study ...